Equitable Trust Co. Cuts Stock Holdings in DaVita Inc. $DVA

Equitable Trust Co. lowered its stake in DaVita Inc. (NYSE:DVA) by 40.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 20,970 shares of the company’s stock after selling 14,347 shares during the period. Equitable Trust Co.’s holdings in DaVita were worth $2,987,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. UMB Bank n.a. increased its holdings in shares of DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $29,000 after buying an additional 76 shares during the last quarter. National Pension Service raised its stake in shares of DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company’s stock worth $30,000 after acquiring an additional 84 shares in the last quarter. Y.D. More Investments Ltd bought a new position in shares of DaVita during the 1st quarter worth approximately $35,000. Ameritas Advisory Services LLC purchased a new stake in DaVita during the 2nd quarter worth approximately $47,000. Finally, NewEdge Advisors LLC raised its stake in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

DaVita stock opened at $123.89 on Tuesday. DaVita Inc. has a 1 year low of $122.93 and a 1 year high of $179.60. The firm has a 50 day moving average price of $132.95 and a 200 day moving average price of $138.97. The company has a market cap of $8.86 billion, a price-to-earnings ratio of 12.18, a PEG ratio of 0.89 and a beta of 1.13.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.70 by $0.25. The business had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

DVA has been the subject of a number of recent analyst reports. Bank of America cut their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Truist Financial set a $148.00 target price on shares of DaVita in a report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Barclays lowered their target price on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a report on Thursday. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $155.25.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider directly owned 26,038 shares of the company’s stock, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is owned by corporate insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.